NCT03804840View on ClinicalTrials.gov

Developing a Mobile Method to Measure THC-induced Impairment

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

December 1, 2018

Study Completion Date

December 1, 2018

Conditions
Measuring THC-induced Cognitive Impairment Using a Mobile Application
Interventions
DRUG

Dronabinol

THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication.

DRUG

Placebo

Placebo

Trial Locations (1)

60615

University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT03804840 - Developing a Mobile Method to Measure THC-induced Impairment | Biotech Hunter | Biotech Hunter